Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals (Nasdaq: SNDX) announced the granting of inducement awards to four new employees on November 1, 2024. The awards consist of stock options to purchase up to 78,700 shares of common stock under the Company's 2023 Inducement Plan. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over the following 36 months, contingent on continued employment with Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX) ha annunciato la concessione di premi di assunzione a quattro nuovi dipendenti il 1° novembre 2024. I premi consistono in opzioni su azioni per l'acquisto di fino a 78.700 azioni ordinarie nell'ambito del Piano di Assunzione 2023 della Società. Le opzioni si matureranno in quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente nei successivi 36 mesi, a condizione di un impiego continuativo presso Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX) anunció la concesión de premios de inducción a cuatro nuevos empleados el 1 de noviembre de 2024. Los premios consisten en opciones de acciones para comprar hasta 78,700 acciones ordinarias bajo el Plan de Inducción 2023 de la Compañía. Las opciones madurarán en cuatro años, con un 25% madurando después de un año y el resto madurando mensualmente durante los siguientes 36 meses, dependiendo de la continuación del empleo con Syndax.
신닥스 제약 (Nasdaq: SNDX)는 2024년 11월 1일 네 명의 신규 직원에게 유인 보상을 제공하기로 발표했습니다. 보상은 회사의 2023 유인 계획에 따라 최대 78,700주의 보통주를 구매할 수 있는 주식 옵션으로 구성됩니다. 이러한 옵션은 4년 동안 점진적으로 부여되며, 1년 후 25%가 부여되고 이후 36개월 동안 매달 나머지가 부여됩니다. 이는 신닥스에서의 지속적인 고용을 조건으로 합니다.
Syndax Pharmaceuticals (Nasdaq: SNDX) a annoncé le 1er novembre 2024 l'octroi de récompenses d'incitation à quatre nouveaux employés. Les récompenses se composent d'options d'achat d'actions, permettant l'achat de jusqu'à 78 700 actions ordinaires dans le cadre du Plan d'Incitation 2023 de la Société. Les options s'échelonneront sur quatre ans, avec 25 % devenant acquises après un an et le reste s'acquérant mensuellement au cours des 36 mois suivants, sous réserve d'un emploi continu chez Syndax.
Syndax Pharmaceuticals (Nasdaq: SNDX) gab am 1. November 2024 die Gewährung von Anreizprämien an vier neue Mitarbeiter bekannt. Die Prämien bestehen aus Aktienoptionen zum Kauf von bis zu 78.700 Aktien im Rahmen des Anreizplans der Gesellschaft von 2023. Die Optionen werden über vier Jahre ausgereicht, wobei 25% nach einem Jahr und der Rest monatlich über die folgenden 36 Monate fällig wird, vorbehaltlich einer fortlaufenden Anstellung bei Syndax.
- None.
- None.
About Syndax
Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827
View original content:https://www.prnewswire.com/news-releases/syndax-pharmaceuticals-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302293985.html
SOURCE Syndax Pharmaceuticals, Inc.
FAQ
How many shares were granted in Syndax Pharmaceuticals (SNDX) inducement awards on November 1, 2024?
What is the vesting schedule for SNDX's November 2024 inducement stock options?
How many employees received SNDX inducement grants in November 2024?
